Shin Nippon Biomedical Laboratories : Notice Regarding Revisions of the Earnings Forecasts for the Six Months and Full-Year of the Fiscal Year Ending March 31, 2023
July 29, 2022 at 07:34 am
Share
Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
July 29, 2022
Company name
Shin Nippon Biomedical Laboratories, Ltd.
Representative
Representative Chairman, President & CEO
Ryoichi Nagata
Listing
TSE PRIME : ticker code 2395
Inquiries
Managing Executive Officer, Senior Director,
Corporate Communications, Toshiyuki Iwata
TEL
+81 3 5565 6216
Notice Regarding Revisions of the Earnings Forecasts
for the Six Months and Full-Year of the Fiscal Year Ending March 31, 2023
Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, "the Company") announces the revisions to the forecast of the first six months and the full-year consolidated results for the fiscal year ending March 31, 2023 (from April 1, 2022 to December 31, 2023) announced on May 6, 2022, in view of the latest earnings trends.
1.Revisions to the forecast of the consolidated results for the fiscal year ending March 31, 2023
(1) Revisions to the forecast of the first six months consolidated financial results from April 1, 2022 to September 30, 2022
Operating
Profit
Profit
Net Sales
Ordinary profit
attributable to
profit
per share
owners of parent
Millions of yen
Millions of yen
Millions of yen
Millions of yen
Yen
Previous Forecasts (A)
9,500
2,450
2,950
2,050
49.24
Revised forecasts (B)
10,570
2,510
4,700
3,310
79.50
Changes (B - A)
+1,070
+60
+1,750
+1,260
Changes (%)
+11.3
+2.4
+59.3
+61.5
ref.)Results of the six months of the
7,961
1,969
2,529
3,503
84.15
fiscal year ended March 31, 2022
(2) Revisions to the forecast of the full year consolidated financial results from April 1, 2022 to March 31, 2023
Net Sales
Operating
Ordinary profit
Profit
Profit
attributable to
profit
per share
owners of parent
Millions of yen
Millions of yen
Millions of yen
Millions of yen
Yen
Previous Forecasts (A)
19,600
5,000
6,000
4,300
103.28
Revised forecasts (B)
22,830
5,210
7,890
5,590
134.27
Changes (B - A)
+3,230
+210
+1,890
+1,290
Changes (%)
+16.5
+4.2
+31.5
+30.0
ref.)Results of the fiscal year ended
17,748
4,195
7,078
7,127
171.20
March 31, 2022
2.Reasons for the revisions to the consolidate financial results forecasts
As announced in the "Notice of Result of Tender Offer for Shares of Common Stock of Ina Research Inc. and Change in Subsidiaries" on July 14, 2022, Ina Research Inc. became Company's consolidated subsidiary on July 20, 2022. Reflecting this event and in consideration of effects of the goodwill amortization related to Ina Research Inc. acquisition and recent foreign exchange and currency trends, the Company revised the consolidated financial forecasts for the fiscal year ending March 31, 2023 as above. The Company's sales, operating profit, ordinary profit and profit attributable to owners of parent are all expected to exceed the original forecast announced in May 2022.
Foreign exchange gain of ¥1,686 million was posted in the first three month of the fiscal year ending March 31, 2023, based on the foreign exchange rate of 136.64 Japanese yen to the US dollar. The newly revised forecast figures in the full-year outlook above are also based on the assumed exchange rate of 136.64 Japanese yen to the US dollar.
(NOTE) Financial forecasts and other statements above are based on information available as of the date of this announcement. Actual performance may differ substantially due to various factors in the future
Attachments
Original Link
Original Document
Permalink
Disclaimer
Shin Nippon Biomedical Laboratories Ltd. published this content on 29 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2022 06:33:03 UTC.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
Shin Nippon Biomedical Laboratories : Notice Regarding Revisions of the Earnings Forecasts for the Six Months and Full-Year of the Fiscal Year Ending March 31, 2023